ATE293102T1 - Naphthalene derivate ,ihre herstellung und verwendung - Google Patents

Naphthalene derivate ,ihre herstellung und verwendung

Info

Publication number
ATE293102T1
ATE293102T1 AT99917102T AT99917102T ATE293102T1 AT E293102 T1 ATE293102 T1 AT E293102T1 AT 99917102 T AT99917102 T AT 99917102T AT 99917102 T AT99917102 T AT 99917102T AT E293102 T1 ATE293102 T1 AT E293102T1
Authority
AT
Austria
Prior art keywords
sup
substituted
group
hydrogen atom
sub
Prior art date
Application number
AT99917102T
Other languages
English (en)
Inventor
Akihiro Tasaka
Akio Ojida
Tomohiro Kaku
Masami Kusaka
Masuo Yamaoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE293102T1 publication Critical patent/ATE293102T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99917102T 1998-04-23 1999-04-22 Naphthalene derivate ,ihre herstellung und verwendung ATE293102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11380198 1998-04-23
PCT/JP1999/002143 WO1999054309A1 (en) 1998-04-23 1999-04-22 Naphthalene derivatives, their production and use

Publications (1)

Publication Number Publication Date
ATE293102T1 true ATE293102T1 (de) 2005-04-15

Family

ID=14621427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99917102T ATE293102T1 (de) 1998-04-23 1999-04-22 Naphthalene derivate ,ihre herstellung und verwendung

Country Status (7)

Country Link
US (2) US6573289B1 (de)
EP (1) EP1073640B1 (de)
AT (1) ATE293102T1 (de)
AU (1) AU3534699A (de)
CA (1) CA2328973A1 (de)
DE (1) DE69924717T2 (de)
WO (1) WO1999054309A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
ATE494388T1 (de) 1999-01-13 2011-01-15 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase- inhibitoren
US6713632B1 (en) 1999-06-22 2004-03-30 Takeda Chemical Industries, Ltd. Process for the preparation of imidazole derivatives
EP1228083A2 (de) * 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutische behandlung von durch androgenrezeptor hervorgerufene erkrankungen
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
WO2001030764A1 (en) * 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
CA2388483A1 (en) 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. Process for producing optically active naphthalene derivative and optical resolver therefor
TWI306099B (en) 2000-11-17 2009-02-11 Takeda Chemical Industries Ltd Novel imidazole derivatives, production method thereof and use thereof
CA2429437A1 (en) * 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
EP1348706B1 (de) 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
EP1424080B1 (de) * 2001-08-10 2011-02-16 Takeda Pharmaceutical Company Limited Gnrh-agonistische kombinationsmittel
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7129225B2 (en) * 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
RU2363696C2 (ru) * 2003-07-10 2009-08-10 Оси Фармасьютикалз, Инк. Производные нафтилена как ингибиторы цитохрома р450
UA86614C2 (ru) * 2004-01-23 2009-05-12 Амген Инк Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
EP1711495A2 (de) 2004-01-23 2006-10-18 Amgen Inc. Chinolin-, chinazolin-, pyridin- und pyrimidinverbindungen und deren verwendung bei der behandlung von entzündungen, angiogenese und krebs
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
AU2005312048B2 (en) * 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
BRPI0706759A2 (pt) * 2006-01-27 2011-04-05 Hofmann La Roche Ag F Uso de derivados de 4-imidazol para distúrbios do cns
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
JP5167265B2 (ja) * 2006-10-19 2013-03-21 エフ.ホフマン−ラ ロシュ アーゲー 微量アミン関連受容体に親和性を有するアミノメチル−2−イミダゾール
CN101528710B (zh) * 2006-10-19 2012-11-07 弗·哈夫曼-拉罗切有限公司 氨基甲基-4-咪唑类
MX2009004617A (es) 2006-11-02 2009-05-22 Hoffmann La Roche 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina.
EP2084152A2 (de) * 2006-11-16 2009-08-05 F. Hoffmann-Roche AG Substituierte 4-imidazole
JP2010513238A (ja) * 2006-12-13 2010-04-30 エフ.ホフマン−ラ ロシュ アーゲー 微量アミン関連受容体(taar)に対するリガンドとしての新規2−イミダゾール
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 taar1 리간드로서 2-아미노옥사졸린
EP2121641B1 (de) * 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazoline als taar1-liganden
MX2009013742A (es) 2007-07-02 2010-01-26 Hoffmann La Roche 2-imidazolinas.
KR101150628B1 (ko) * 2007-07-03 2012-05-31 에프. 호프만-라 로슈 아게 4-이미다졸린 및 항우울제로서 이의 용도
WO2009016048A1 (en) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
KR20100039429A (ko) * 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 Cns 질환의 치료를 위한 벤즈아미드 유도체의 용도
JP5341084B2 (ja) * 2007-08-03 2013-11-13 エフ.ホフマン−ラ ロシュ アーゲー Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
US7795254B2 (en) * 2007-10-29 2010-09-14 Amgen Inc. Benzomorpholine derivatives and methods of use
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
MX2011000464A (es) * 2008-07-24 2011-03-01 Hoffmann La Roche Derivados de 4,5-dihidro-oxazol-2-ilo.
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
AU2010339691B2 (en) 2010-01-07 2015-04-02 Alkermes Pharma Ireland Limited Prodrugs of heteraromatic compounds
EP2600855A2 (de) 2010-08-04 2013-06-12 Pellficure Pharmaceuticals, Inc. Kombinationstherapie zur behandlung von prostatakarzinom
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
EA024197B1 (ru) * 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
WO2013033004A2 (en) * 2011-08-30 2013-03-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2014241816B9 (en) 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
EP3191087A1 (de) 2014-09-12 2017-07-19 Pellficure Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von prostatakrebs
BR112018015389B1 (pt) 2016-03-17 2023-12-19 F. Hoffmann-La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso
EP3528799A1 (de) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen aus 5-hydroxy-2-methylnaphthalen-1,4-dion
CN114213296B (zh) * 2021-12-23 2024-01-26 中节能万润股份有限公司 含异硫氰基的萘系列液晶单体化合物以及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1154722A (en) * 1965-07-08 1969-06-11 Boots Pure Drug Co Ltd 2,4,5-Tribromoimidazole Derivatives and Compositions thereof
US3759934A (en) 1970-12-09 1973-09-18 Sandoz Ag 2,3 or 4-pyri dinemethanol-alpha-substituted or unsubstituted phenyls-alpha-(2 or 3-alkoxy-1-naphthyls)
EP0098690B1 (de) 1982-06-14 1987-09-09 Takeda Chemical Industries, Ltd. Vinylcarbonsäure-Derivate, ihre Herstellung und Verwendung
DE3508903A1 (de) 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3777366D1 (de) 1986-12-27 1992-04-16 Takeda Chemical Industries Ltd 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
FR2617478B1 (fr) * 1987-07-01 1990-01-05 Esteve Labor Dr Nouveaux derives d'aryl-heteroaryl cetones, leur procede de preparation ainsi que leur application a titre de medicament
WO1992016527A1 (fr) 1991-03-22 1992-10-01 Nippon Soda Co., Ltd. Derive de pyridine substitue en position 2, sa production, et bactericide d'agrohorticulture
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
SE9302333D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
PL313769A1 (en) 1993-09-30 1996-07-22 Yamanouchi Pharma Co Ltd Azole derivative and pharmaceutical composition thereof
KR19980702319A (ko) 1995-03-01 1998-07-15 오노다 마사요시 이미다졸 유도체 및 이의 의약 조성물
AU710875B2 (en) 1995-12-06 1999-09-30 Tokuyama Corporation Chromene compounds and photochromic materials
US6713632B1 (en) * 1999-06-22 2004-03-30 Takeda Chemical Industries, Ltd. Process for the preparation of imidazole derivatives
WO2001003073A1 (de) * 1999-07-06 2001-01-11 Gsi Gesellschaft Für Systemtechnik Und Informatik Mbh Vorrichtung zur flexiblen gebührenerfassung
CA2388483A1 (en) 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. Process for producing optically active naphthalene derivative and optical resolver therefor

Also Published As

Publication number Publication date
US7084149B2 (en) 2006-08-01
EP1073640B1 (de) 2005-04-13
WO1999054309A1 (en) 1999-10-28
EP1073640A1 (de) 2001-02-07
US6573289B1 (en) 2003-06-03
AU3534699A (en) 1999-11-08
US20030236274A1 (en) 2003-12-25
DE69924717D1 (de) 2005-05-19
CA2328973A1 (en) 1999-10-28
DE69924717T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
ATE293102T1 (de) Naphthalene derivate ,ihre herstellung und verwendung
DE60034785D1 (en) 1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2-pyrazoline als cyclooxygenase-2 inhibitoren
WO2001056989A3 (en) Inhibitors of factor xa
ATE440096T1 (de) Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung
DE69532817D1 (de) Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
BRPI0615111B8 (pt) composto, composição farmacêutica, e, uso do composto
DE69734773D1 (de) Nicht-peptidische bombesin rezeptor antagonisten
PL338352A1 (en) Derivatives of 1-(n-phenylaminoalkyl)-piperazine substituted at position 2 of its phenyl ring
NO964095L (no) Nye hydroksypyridinoner
EP0974584A4 (de) Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung
DE69940320D1 (de) Betulinsäurederivate zur inhibierung des krebswach
DE69911935D1 (de) Granulatimide-derivate zur behandlung von krebs
DK1056704T3 (da) Antitumormidler
PL341050A1 (en) Heterocyclic cytoxic agents
ES8602739A1 (es) Procedimiento para la fabricacion de nuevos derivados de la cumarina
AU2001255646A1 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
ATE321552T1 (de) 1-substituierte-phenyl-1-(1h-imidazol-4- yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
DE60108089D1 (de) Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel
DE69521687D1 (de) 4-indol-1-yl-buttersäure derivate, deren herstellung und deren verwendung als inhibitoren für alpha1-adrenerge rezeptoren und testosteron 5alpha-reduktasen
ATE229538T1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
Hassan et al. Synthesis of novel spiro (indolone‐3, 2′‐[1, 3, 4] thiadiazol)‐2‐ones and evaluation of their antidepressant and anticonvulsant activities
ES2043820T3 (es) Nuevas 1-1 alkil-1-sulfonil-2-alkoxicarbonilsulfenilhidrazinas que tienen actividad antineoplastica.
Karaali et al. Synthesis and urease inhibition study of some new quinazolinone derivatives bearing triazole, thiadiazole, and piperazine moiety
WO2000010543A3 (de) Arzneimittel enthaltend platinkomplexverbindungen sowie deren verwendung
GB2373499A (en) Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties